<DOC>
	<DOCNO>NCT00288028</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Giving bortezomib autologous peripheral blood stem cell transplant may stop growth cancer cell remain transplant . PURPOSE : This phase I trial study side effect best dose bortezomib treat patient multiple myeloma undergone autologous peripheral blood stem cell transplant .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Multiple Myeloma Who Have Undergone Autologous Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) bortezomib maintenance phase high-dose melphalan autologous peripheral blood stem cell transplantation patient multiple myeloma . - Determine safety tolerability bortezomib patient . Secondary - Determine overall response rate , complete response rate , response duration patient treat bortezomib MTD . OUTLINE : This open-label , dose-finding study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 . Treatment repeat every 21 28 day 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive de-escalating dos bortezomib ( vary dose schedule ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . After completion study treatment , patient follow 1 year . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma Must complete highdose melphalan autologous peripheral blood stem cell transplantation Transplant must complete 30120 day ago Must receive maintenance therapy Patients must receive 200 mg/m² melphalan intravenously condition regimen ( dose reduction allow ) No evidence amyloidosis No available donor PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 75,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal Transaminase ≤ 3 time upper limit normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Must negative HIV test No baseline neurological disease &gt; grade I No cranial nerve palsy No demonstrate resistance bortezomib No history allergic reaction attribute bortezomib , boron , mannitol No cardiac arrhythmia No unstable angina pectoris No symptomatic congestive heart failure No ongoing active infection No uncontrolled illness No psychiatric illness social situation would limit compliance study requirement PRIOR CONCURRENT THERAPY : See Disease Characteristics No concurrent anticancer therapy agents No concurrent investigational agent Not receive maintenance therapy prior stem cell transplantation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>